Shockwave Medical Announces Key Activities for Transcatheter Therapeutics Meeting 2016

- Primary endpoint from DISRUPT CAD, first prospective study of Lithoplasty in calcified coronary lesions
- Data from DISRUPT PAD for treatment of peripheral arteries
- Sponsored Satellite Symposium to be held October 31

Fremont, Calif. — October 26, 2016 — Shockwave Medical, a pioneer in the treatment of calcified cardiovascular disease, today announced the company's key activities at the annual Transcatheter Cardiovascular Therapeutics Meeting (TCT) taking place at the Washington Convention Center in Washington, D.C.

Data from the recently fully enrolled DISRUPT CAD Study, the first study to evaluate the use of the Shockwave Medical Coronary Lithoplasty® System to treat calcified coronary lesions, will be presented as will data on the treatment of peripheral arteries from the DISRUPT PAD Study.

Shockwave Medical's TCT conference activities include:

Monday, October 31

- Satellite Presentation Theatre Program: Treating Calcified Peripheral Vascular Arteries with the Shockwave Medical Lithoplasty® System at 11:30 am in Presentation Theatre 5, Exhibit Hall, Level 2. Faculty include William Gray, MD, Kenneth Rosenfield, M.D., Michael Jaff, D.O., Martin Werner, M.D. and Todd J. Brinton, M.D.

- DISRUPT CAD: A multicenter, prospective, single-arm study of percutaneous Lithoplasty prior to stent implantation in calcified coronary lesions, will be presented by Todd J. Brinton, M.D., co-founder of Shockwave Medical, at 12:48 pm in Room 150, Level 1

- Calcium disruption with coronary Lithoplasty: Use of the Shockwave Balloon in complex disease, will be presented by Ian T. Meredith. M.D. at 4:16 pm, Room 150, Level 1

Tuesday, November 1

- Data from DISRUPT PAD: Safety and Performance of the Shockwave Medical Lithoplasty System in Treating Calcified Peripheral Vascular Lesions: 6-Month Results from the Two-Phase DISRUPT PAD Study, will be presented by Todd J. Brinton, M.D. at 9:03 am, Room 209, Level 2

The Peripheral Lithoplasty System will be featured in Booth #1344 at TCT.

Shockwave Medical's Peripheral Lithoplasty System received clearance from the U.S. Food and Drug Administration (FDA) for use in the peripheral vasculature, including the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries. Not intended for use in the coronary or cerebral vasculature.

The Coronary Lithoplasty System is an investigational device and is not available for sale.

About Shockwave Medical's Peripheral Lithoplasty® Systems

The Lithoplasty System integrates the calcium-disrupting power of lithotripsy with the familiarity and simplicity of angioplasty balloon-based devices. Built on a balloon catheter platform, the Shockwave Medical Lithoplasty System uses lithotripsy to disrupt both superficial and deep vascular calcium, while minimizing soft tissue injury, and an integrated angioplasty balloon to dilate blockages at low pressures, restoring blood flow. The Peripheral Lithoplasty System is commercially available in the European Union and the United States for treatment of peripheral vascular disease.

To view an animation of the Peripheral Lithoplasty System visit: http://shockwavemedical.com.

About Shockwave Medical

Shockwave Medical, based in Fremont, Calif., is working to reshape interventional therapy with Lithoplasty® Technology for the treatment of calcified peripheral vascular, coronary vascular and heart valve disease. For more information, visit www.shockwavemedical.com.

###

Media Contact:
Jessica Volchok
jessica@nicoleosmer.com
310.849.7985